几种重要微生物抗肿瘤作用研究进展
|
摘要
微生物的抗肿瘤作用已被广泛报道,目前,多种微生物已被应用于临床治疗,如卡介苗、Ⅰ型单纯疱疹病毒、腺病毒等。与传统肿瘤疗法相比,微生物疗法具有靶向性好、对机体造成的损伤很小甚至没有、可用于治疗恶性癌症晚期等优点,但是,该疗法在差异较大的个体间临床治疗效果差异较大。研发新型的肿瘤生物疗法,探究其作用机制和途径具有重要的临床意义。现对已报道的微生物抗肿瘤作用及其反应机制进行梳理总结和综述分析,以期为开发新型微生物抗肿瘤疗法和研究微生物、肿瘤细胞、免疫系统三者间相互作用提供参考。
The antitumor effects of microorganisms have been widely reported, and some microorganisms were applied to clinical therapy successfully, such as BCG, HSV-1 and adenovirus. Biological therapy has some advantages, including great targeting, less or even no injury to body, and it can be used to treat late stage of malignant cancer. However,biological therapy has disadvantages at the same time, such as the lower rate of response to some individuals. It is significant to develop novel biological therapy and investigate the mechanism by which microorganisms use to induce antitumor effect. This paper makes a clear summary and review on research progress of antitumor effect of microorganisms, aiming at laying a foundation for development of novel antitumor drugs, and providing reference for exploring the complex relationship among microorganism, tumor cell and immune system.
The antitumor effects of microorganisms have been widely reported, and some microorganisms were applied to clinical therapy successfully, such as BCG, HSV-1 and adenovirus. Biological therapy has some advantages, including great targeting, less or even no injury to body, and it can be used to treat late stage of malignant cancer. However,biological therapy has disadvantages at the same time, such as the lower rate of response to some individuals. It is significant to develop novel biological therapy and investigate the mechanism by which microorganisms use to induce antitumor effect. This paper makes a clear summary and review on research progress of antitumor effect of microorganisms, aiming at laying a foundation for development of novel antitumor drugs, and providing reference for exploring the complex relationship among microorganism, tumor cell and immune system.
引文
[1]Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015.CA Cancer J Clin,2016,66:115-32
[2]Twumasi-Boateng K,Pettigrew JL,Kwok Y,et al.Oncolytic viruses as engineering platforms for combination immunotherapy.Nat Rev Cancer,2018,18:419-32
[3]Kienle GS.Fever in cancer treatment:Coley’s therapy and epidemiologic observations.Glob Adv Health Med,2012,1:92-100
[4]刘尚龙,戴梦华,由磊,等.单纯疱疹病毒治疗肿瘤的研究新进展.中国科学:生命科学,2013,43:283-90
[5]Oddens J,Brausi M,Sylvester R,et al.Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Guérin in intermediateand high-risk Ta,T1 papillary carcinoma of the urinary bladder:one-third dose versus full dose and 1 year versus3 years of maintenance.Eur Urol,2013,63:462-72
[6]Matsumoto Y,Miwa S,Zhang Y,et al.Efficacy of tumortargeting Salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer.J Cell Biochem,2014,115:1996-2003
[7]Sivan A,Corrales L,Hubert N,et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science,2015,350:1084-9
[8]Vétizou M,Pitt JM,Daillère R,et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science,2015,350:1079-84
[9]Jiang H,Dong H,Peng X,et al.Transcriptome analysis of gene expression profiling of infected macrophages between Brucella suis 1330 and live attenuated vaccine strain S2 displays mechanistic implication for regulation of virulence.Microb Pathog,2018,119:241-7
[10]Russell SJ,Peng KW.Oncolytic virotherapy:a contest between apples and oranges.Mol Ther,2017,25:1107-16
[11]Howells A,Marelli G,Lemoine NR,et al.Oncolytic viruses-interaction of virus and tumor cells in the battle to eliminate cancer.Front Oncol,2017,7:195
[12]Benencia F,Courrèges MC,Conejo-García JR,et al.HSVoncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer.Mol Ther,2005,12:789-802
[13]Yu W,Fang H.Clinical trials with oncolytic adenovirus in China.Curr Cancer Drug Targets,2007,7:141-8
[14]Samson A,Scott KJ,Taggart D,et al.Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.Sci Transl Med,2018,10:pii:eaam7577
[15]Mell LK,Brumund KT,Daniels GA,et al.Phase i trial of intravenous oncolytic vaccinia virus(GL-ONC1)with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma.Clin Cancer Res,2017,23:5696-702
[16]Marchini A,Bonifati S,Scott EM,et al.Oncolytic parvoviruses:from basic virology to clinical applications.Virol J,2015,12:6
[17]Koks CA,Garg AD,Ehrhardt M,et al.Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.Int J Cancer,2015,136:E313-25
[18]Burke MJ.Oncolytic Seneca Valley virus:past perspectives and future directions.Oncolytic Virother,2016,5:81-9
[19]Varghese S,Rabkin SD.Oncolytic herpes simplex virus vectors for cancer virotherapy.Cancer Gene Ther,2002,9:967-78
[20]Patel DM,Foreman PM,Nabors LB,et al.Design of a phase I clinical trial to evaluate M032,a genetically engineered HSV-1 expressing IL-12,in patients with recurrent/progressive glioblastoma multiforme,anaplastic astrocytoma,or gliosarcoma.Hum Gene Ther Clin Dev,2016,27:69-78
[21]Janke M,Peeters B,de Leeuw O,et al.Recombinant Newcastle disease virus(NDV)with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.Gene Ther,2007,14:1639-49
[22]Samson A,Bentham MJ,Scott K,et al.Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.Gut,2018,67:562-73
[23]HamidO,HoffnerB,GasalE,etal.Oncolytic immunotherapy:unlocking the potential of viruses to help target cancer.Cancer Immunol Immunother,2017,66:1249-64
[24]Harrington KJ,Puzanov I,Hecht JR,et al.Clinical development of talimogene laherparepvec(T-VEC):a modified herpes simplex virus type-1-derived oncolytic immunotherapy.Expert Rev Anticancer Ther,2015,15:1389-403
[25]Andtbacka RH,Kaufman HL,Collichio F,et al.Talimogene laherparepvec improdurable response rate in patients with advanced melanoma.J Clin Oncol,2015,33:2780-8
[26]Goshima F,Esaki S,Luo C,et al.Oncolytic viral therapy with a combination of HF10,a herpes simplex virus type1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.Int J Cancer,2014,134:2865-77
[27]Liu XJ,Wang XY,Guo JX,et al.Oncolytic property of HSV-1 recombinant viruses carrying the human IL-12.Zhonghua Yi Xue Za Zhi,2017,97:2135-40
[28]Workenhe ST,Simmons G,Pol JG,et al.Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.Mol Ther,2014,22:123-31
[29]Cassel WA,Garrett RE.Newcastle disaease virus as an antineoplastic agent.Cancer,1965,18:863-8
[30]Yurchenko KS,Zhou P,Kovner AV,et al.Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model.PLoSOne,2018,13:e0195425
[31]Wu Y,He J,An Y,et al.Recombinant Newcastle disease virus(NDV/Anh-IL-2)expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy.J Pharmacol Sci,2016,132:24-30
[32]Xu X,Sun Q,Mei Y,et al.Newcastle disease virus coexpressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy.Cancer Sci,2018,109:279-88
[33]Zamarin D,Holmgaard RB,Ricca J,et al.Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic antitumour immunity.Nat Commun,2017,8:14340
[34]Zamarin D,Holmgaard RB,Subudhi SK,et al.Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.Sci Transl Med,2014,6:226-32
[35]Fournier P,Bian H,Szeberenyi J,et al.Analysis of three properties of Newcastle disease virus for fighting cancer:tumor-selective replication,antitumor cytotoxicity,and immunostimulation.Methods Mol Biol,2012,797:177-204
[36]王玢瑸.新城疫病毒激活NLRP3炎症小体及其作用[D].北京:中国农业科学院,2016
[37]Ginting TE,Suryatenggara J,Christian S,et al.Proinflammatory response induced by Newcastle disease virus in tumor and normal cells.Oncolytic Virother,2017,6:21-30
[38]Ortega-Rivera OA,Quintanar JL,Del TS,et al.Antitumor and immunostimulatory activities of a genotype Vrecombinant attenuated veterinary Newcastle disease virus vaccine.Oncol Lett,2018,15:1246-54
[39]Pease DF,Kratzke RA.Oncolytic viral therapy for mesothelioma.Front Oncol,2017,7:179
[40]Kuryk L,Moller AW,Garofalo M,et al.Antitumorspecific T-cell responses induced by oncolytic adenovirus ONCOS-102(AdV5/3-D24-GM-CSF)in peritoneal mesothelioma mouse model.J Med Virol,2018,90:1669-73
[41]He X,Peng X,Liu Y,et al.Adenovirus-mediated overexpression FADD induces a significant antitumor effect on human colorectal cancer cells both in vitro and in vivo.Cell Mol Biol(Noisy-le-grand),2018,64:31-5
[42]Lichtenegger E,Koll F,Haas H,et al.The oncolytic adenovirus XVir-N-31 as a novel therapy in muscleinvasive bladder cancer.Hum Gene Ther,2019,30:44-56
[43]Garber K.China approves world’s first oncolytic virus therapy for cancer treatment.J Natl Cancer Inst,2006,98:298-300
[44]Ranki T,Pesonen S,Hemminki A,et al.Phase I study with ONCOS-102 for the treatment of solid tumors--an evaluation of clinical response and exploratory analyses of immune markers.J Immunother Cancer,2016,4:17
[45]Ranki T,Joensuu T,Jager E,et al.Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+T-cell response,prominent in filtration of CD8+ lymphocytes and Th1 type polarization.Oncoimmunology,2014,3:e958937
[46]Vassilev L,Ranki T,Joensuu T,et al.Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.Oncoimmunology,2015,4:e1017702
[47]Frahm M,Felgner S,Kocijancic D,et al.Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy.MBio,2015,6:pii:e00254-15
[48]Zhang H,Diao H,Jia L,et al.Proteus mirabilis inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model.PLoS One,2017,12:e0188960
[49]Lee CH.Employment of Salmonella in cancer gene therapy.Methods Mol Biol,2016,1409:79-83
[50]Morales A,Eidinger D,Bruce AW.Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors.J Urol,1976,116:180-3
[51]张敏,骆菲菲,黄恩宇,等.PA-MSHA抗肿瘤效应的免疫机制研究.复旦学报:医学版,2015,42:13-7
[52]Fisher B,Gebhardt M,Linta J,et al.Comparison of the inhibition of tumor growth following local or systemic administration of Corynebacterium parvum or other immunostimulating agents with or without cyclophos phamide.Cancer Res,1978,38:2679-87
[53]Sanchez-Rodriguez C,Cruces KP,Riestra AJ,et al.BCGimmune activation reduces growth and angiogenesis in an in vitro model of head and neck squamous cell carcinoma.Vaccine,2017,35:6395-403
[54]Gomes-Giacoia E,Miyake M,Goodison S,et al.Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model;a role for cytokine production and NK cell expansion.PLoS One,2014,9:e96705
[55]Sun E,Nian X,Liu C,et al.Construction of recombinant human IFNα-2b BCG and its antitumor effects on bladder cancer cells in vitro.Genet Mol Res,2015,14:3436-49
[56]Takeuchi A,Eto M,Tatsugami K,et al.Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.Int Immunopharmacol,2016,35:327-31
[57]Forbes NS,Munn LL,Fukumura D,et al.Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors.Cancer Res,2003,63:5188-93
[58]Toso JF,Gill VJ,Hwu P,et al.Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.J Clin Oncol,2002,20:142-52
[59]Hoffman RM.Tumor-targeting Salmonella typhimurium A1-R:an overview.Methods Mol Biol,2016,1409:1-8
[60]Tu DG,Chang WW,Lin ST,et al.Salmonella inhibits tumor angiogenesis by downregulation of vascular endothelial growth factor.Oncotarget,2016,7:37513-23
[61]Kuan YD,Lee CH.Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2,3-dioxygenase 1 expression.Oncotarget,2016,7:374-85
[62]Snyder A,Pamer E,Wolchok J.Could microbial therapy boost cancer immunotherapy.Science,2015,350:1031-2
[63]刘娟,曹雪涛.2017年国内外免疫学研究重要进展.中国免疫学杂志,2018,34:1-10
[64]Routy B,Le Chatelier E,Derosa L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science,2018,359:91-7
[65]Gopalakrishnan V,Spencer CN,Nezi L,et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science,2018,359:97-103
[66]Hirnle Z.The effect of Brucella abortus infection on transmissible Crocker’s sarcoma in mice.Acta Med Pol,1960,1:219-41
[67]Veskova TK,Chimishkyan KL,Sver-Moldavsky GJ.Effect of Brucella abortus infection(vaccine strain 19BA)on Rauscher leukemia virus and L1210 leukemia in mice.J Natl Cancer Inst,1974,52:1651-3
[68]Schultz RM,Pavlidis NA,Chirigos MA.Macrophage involvement in the antitumor activity of Brucella abortus ether extract against experimental lung carcinoma metastases.Cancer Res,1978,38:3427-31
[69]Keleti G,Feingold DS,Youngner JS.Antitumor activity of a Brucella abortus preparation.Infect Immun,1977,15:846-9
[70]Chirigos MA,Stylos WA,Schultz RM et al.Chemical and biological adjuvants capable of potentiating tumor cell vaccine.Cancer Res,1978,38:1085-91
[71]Dazord L,Le Garrec Y,David C,et al.Resistance to transplanted cancer in mice increased by live Brucella vaccine.Br J Cancer,1978,38:464-7
[72]Dazord L,le Garrec Y,Florentin I.Antitumor activity of living or killed Brucella:modification of the non-specific cytotoxic effector cells.Cancer Immunol Immunother,1983,15:63-7
[73]Glasgow LA,Crane JJ,Schleupner CJ,et al.Enhancement of resistance to murine osteogenic sarcoma in vivo by an extract of Brucella abortus(Bru-Pel):association with activation of reticuloendothelial system macrophages.Infect Immun,1979,23:19-26
[74]Rossi AH,Farias A,Fernandez JE,et al.Brucella spp.lumazine synthase induces a TLR4-mediated protective response against B16 melanoma in mice.PLoS One,2015,10:e0126827
[75]Coria LM,Ibanez AE,Tkach M,et al.A Brucella spp.protease inhibitor limits antigen lysosomal proteolysis,increases cross-presentation,and enhances CD8+T cell responses.J Immunol,2016,196:4014-29
[76]Robert C.Checkpoint blockade plus oncolytic virus:a hot therapeutic cancer strategy.Trends Mol Med,2017,23:983-5
[2]Twumasi-Boateng K,Pettigrew JL,Kwok Y,et al.Oncolytic viruses as engineering platforms for combination immunotherapy.Nat Rev Cancer,2018,18:419-32
[3]Kienle GS.Fever in cancer treatment:Coley’s therapy and epidemiologic observations.Glob Adv Health Med,2012,1:92-100
[4]刘尚龙,戴梦华,由磊,等.单纯疱疹病毒治疗肿瘤的研究新进展.中国科学:生命科学,2013,43:283-90
[5]Oddens J,Brausi M,Sylvester R,et al.Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Guérin in intermediateand high-risk Ta,T1 papillary carcinoma of the urinary bladder:one-third dose versus full dose and 1 year versus3 years of maintenance.Eur Urol,2013,63:462-72
[6]Matsumoto Y,Miwa S,Zhang Y,et al.Efficacy of tumortargeting Salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer.J Cell Biochem,2014,115:1996-2003
[7]Sivan A,Corrales L,Hubert N,et al.Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy.Science,2015,350:1084-9
[8]Vétizou M,Pitt JM,Daillère R,et al.Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota.Science,2015,350:1079-84
[9]Jiang H,Dong H,Peng X,et al.Transcriptome analysis of gene expression profiling of infected macrophages between Brucella suis 1330 and live attenuated vaccine strain S2 displays mechanistic implication for regulation of virulence.Microb Pathog,2018,119:241-7
[10]Russell SJ,Peng KW.Oncolytic virotherapy:a contest between apples and oranges.Mol Ther,2017,25:1107-16
[11]Howells A,Marelli G,Lemoine NR,et al.Oncolytic viruses-interaction of virus and tumor cells in the battle to eliminate cancer.Front Oncol,2017,7:195
[12]Benencia F,Courrèges MC,Conejo-García JR,et al.HSVoncolytic therapy upregulates interferon-inducible chemokines and recruits immune effector cells in ovarian cancer.Mol Ther,2005,12:789-802
[13]Yu W,Fang H.Clinical trials with oncolytic adenovirus in China.Curr Cancer Drug Targets,2007,7:141-8
[14]Samson A,Scott KJ,Taggart D,et al.Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.Sci Transl Med,2018,10:pii:eaam7577
[15]Mell LK,Brumund KT,Daniels GA,et al.Phase i trial of intravenous oncolytic vaccinia virus(GL-ONC1)with cisplatin and radiotherapy in patients with locoregionally advanced head and neck carcinoma.Clin Cancer Res,2017,23:5696-702
[16]Marchini A,Bonifati S,Scott EM,et al.Oncolytic parvoviruses:from basic virology to clinical applications.Virol J,2015,12:6
[17]Koks CA,Garg AD,Ehrhardt M,et al.Newcastle disease virotherapy induces long-term survival and tumor-specific immune memory in orthotopic glioma through the induction of immunogenic cell death.Int J Cancer,2015,136:E313-25
[18]Burke MJ.Oncolytic Seneca Valley virus:past perspectives and future directions.Oncolytic Virother,2016,5:81-9
[19]Varghese S,Rabkin SD.Oncolytic herpes simplex virus vectors for cancer virotherapy.Cancer Gene Ther,2002,9:967-78
[20]Patel DM,Foreman PM,Nabors LB,et al.Design of a phase I clinical trial to evaluate M032,a genetically engineered HSV-1 expressing IL-12,in patients with recurrent/progressive glioblastoma multiforme,anaplastic astrocytoma,or gliosarcoma.Hum Gene Ther Clin Dev,2016,27:69-78
[21]Janke M,Peeters B,de Leeuw O,et al.Recombinant Newcastle disease virus(NDV)with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy.Gene Ther,2007,14:1639-49
[22]Samson A,Bentham MJ,Scott K,et al.Oncolytic reovirus as a combined antiviral and anti-tumour agent for the treatment of liver cancer.Gut,2018,67:562-73
[23]HamidO,HoffnerB,GasalE,etal.Oncolytic immunotherapy:unlocking the potential of viruses to help target cancer.Cancer Immunol Immunother,2017,66:1249-64
[24]Harrington KJ,Puzanov I,Hecht JR,et al.Clinical development of talimogene laherparepvec(T-VEC):a modified herpes simplex virus type-1-derived oncolytic immunotherapy.Expert Rev Anticancer Ther,2015,15:1389-403
[25]Andtbacka RH,Kaufman HL,Collichio F,et al.Talimogene laherparepvec improdurable response rate in patients with advanced melanoma.J Clin Oncol,2015,33:2780-8
[26]Goshima F,Esaki S,Luo C,et al.Oncolytic viral therapy with a combination of HF10,a herpes simplex virus type1 variant and granulocyte-macrophage colony-stimulating factor for murine ovarian cancer.Int J Cancer,2014,134:2865-77
[27]Liu XJ,Wang XY,Guo JX,et al.Oncolytic property of HSV-1 recombinant viruses carrying the human IL-12.Zhonghua Yi Xue Za Zhi,2017,97:2135-40
[28]Workenhe ST,Simmons G,Pol JG,et al.Immunogenic HSV-mediated oncolysis shapes the antitumor immune response and contributes to therapeutic efficacy.Mol Ther,2014,22:123-31
[29]Cassel WA,Garrett RE.Newcastle disaease virus as an antineoplastic agent.Cancer,1965,18:863-8
[30]Yurchenko KS,Zhou P,Kovner AV,et al.Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model.PLoSOne,2018,13:e0195425
[31]Wu Y,He J,An Y,et al.Recombinant Newcastle disease virus(NDV/Anh-IL-2)expressing human IL-2 as a potential candidate for suppresses growth of hepatoma therapy.J Pharmacol Sci,2016,132:24-30
[32]Xu X,Sun Q,Mei Y,et al.Newcastle disease virus coexpressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy.Cancer Sci,2018,109:279-88
[33]Zamarin D,Holmgaard RB,Ricca J,et al.Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic antitumour immunity.Nat Commun,2017,8:14340
[34]Zamarin D,Holmgaard RB,Subudhi SK,et al.Localized oncolytic virotherapy overcomes systemic tumor resistance to immune checkpoint blockade immunotherapy.Sci Transl Med,2014,6:226-32
[35]Fournier P,Bian H,Szeberenyi J,et al.Analysis of three properties of Newcastle disease virus for fighting cancer:tumor-selective replication,antitumor cytotoxicity,and immunostimulation.Methods Mol Biol,2012,797:177-204
[36]王玢瑸.新城疫病毒激活NLRP3炎症小体及其作用[D].北京:中国农业科学院,2016
[37]Ginting TE,Suryatenggara J,Christian S,et al.Proinflammatory response induced by Newcastle disease virus in tumor and normal cells.Oncolytic Virother,2017,6:21-30
[38]Ortega-Rivera OA,Quintanar JL,Del TS,et al.Antitumor and immunostimulatory activities of a genotype Vrecombinant attenuated veterinary Newcastle disease virus vaccine.Oncol Lett,2018,15:1246-54
[39]Pease DF,Kratzke RA.Oncolytic viral therapy for mesothelioma.Front Oncol,2017,7:179
[40]Kuryk L,Moller AW,Garofalo M,et al.Antitumorspecific T-cell responses induced by oncolytic adenovirus ONCOS-102(AdV5/3-D24-GM-CSF)in peritoneal mesothelioma mouse model.J Med Virol,2018,90:1669-73
[41]He X,Peng X,Liu Y,et al.Adenovirus-mediated overexpression FADD induces a significant antitumor effect on human colorectal cancer cells both in vitro and in vivo.Cell Mol Biol(Noisy-le-grand),2018,64:31-5
[42]Lichtenegger E,Koll F,Haas H,et al.The oncolytic adenovirus XVir-N-31 as a novel therapy in muscleinvasive bladder cancer.Hum Gene Ther,2019,30:44-56
[43]Garber K.China approves world’s first oncolytic virus therapy for cancer treatment.J Natl Cancer Inst,2006,98:298-300
[44]Ranki T,Pesonen S,Hemminki A,et al.Phase I study with ONCOS-102 for the treatment of solid tumors--an evaluation of clinical response and exploratory analyses of immune markers.J Immunother Cancer,2016,4:17
[45]Ranki T,Joensuu T,Jager E,et al.Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8+T-cell response,prominent in filtration of CD8+ lymphocytes and Th1 type polarization.Oncoimmunology,2014,3:e958937
[46]Vassilev L,Ranki T,Joensuu T,et al.Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8+T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer.Oncoimmunology,2015,4:e1017702
[47]Frahm M,Felgner S,Kocijancic D,et al.Efficiency of conditionally attenuated Salmonella enterica serovar Typhimurium in bacterium-mediated tumor therapy.MBio,2015,6:pii:e00254-15
[48]Zhang H,Diao H,Jia L,et al.Proteus mirabilis inhibits cancer growth and pulmonary metastasis in a mouse breast cancer model.PLoS One,2017,12:e0188960
[49]Lee CH.Employment of Salmonella in cancer gene therapy.Methods Mol Biol,2016,1409:79-83
[50]Morales A,Eidinger D,Bruce AW.Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors.J Urol,1976,116:180-3
[51]张敏,骆菲菲,黄恩宇,等.PA-MSHA抗肿瘤效应的免疫机制研究.复旦学报:医学版,2015,42:13-7
[52]Fisher B,Gebhardt M,Linta J,et al.Comparison of the inhibition of tumor growth following local or systemic administration of Corynebacterium parvum or other immunostimulating agents with or without cyclophos phamide.Cancer Res,1978,38:2679-87
[53]Sanchez-Rodriguez C,Cruces KP,Riestra AJ,et al.BCGimmune activation reduces growth and angiogenesis in an in vitro model of head and neck squamous cell carcinoma.Vaccine,2017,35:6395-403
[54]Gomes-Giacoia E,Miyake M,Goodison S,et al.Intravesical ALT-803 and BCG treatment reduces tumor burden in a carcinogen induced bladder cancer rat model;a role for cytokine production and NK cell expansion.PLoS One,2014,9:e96705
[55]Sun E,Nian X,Liu C,et al.Construction of recombinant human IFNα-2b BCG and its antitumor effects on bladder cancer cells in vitro.Genet Mol Res,2015,14:3436-49
[56]Takeuchi A,Eto M,Tatsugami K,et al.Antitumor activity of recombinant Bacille Calmette-Guérin secreting interleukin-15-Ag85B fusion protein against bladder cancer.Int Immunopharmacol,2016,35:327-31
[57]Forbes NS,Munn LL,Fukumura D,et al.Sparse initial entrapment of systemically injected Salmonella typhimurium leads to heterogeneous accumulation within tumors.Cancer Res,2003,63:5188-93
[58]Toso JF,Gill VJ,Hwu P,et al.Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma.J Clin Oncol,2002,20:142-52
[59]Hoffman RM.Tumor-targeting Salmonella typhimurium A1-R:an overview.Methods Mol Biol,2016,1409:1-8
[60]Tu DG,Chang WW,Lin ST,et al.Salmonella inhibits tumor angiogenesis by downregulation of vascular endothelial growth factor.Oncotarget,2016,7:37513-23
[61]Kuan YD,Lee CH.Salmonella overcomes tumor immune tolerance by inhibition of tumor indoleamine 2,3-dioxygenase 1 expression.Oncotarget,2016,7:374-85
[62]Snyder A,Pamer E,Wolchok J.Could microbial therapy boost cancer immunotherapy.Science,2015,350:1031-2
[63]刘娟,曹雪涛.2017年国内外免疫学研究重要进展.中国免疫学杂志,2018,34:1-10
[64]Routy B,Le Chatelier E,Derosa L,et al.Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors.Science,2018,359:91-7
[65]Gopalakrishnan V,Spencer CN,Nezi L,et al.Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.Science,2018,359:97-103
[66]Hirnle Z.The effect of Brucella abortus infection on transmissible Crocker’s sarcoma in mice.Acta Med Pol,1960,1:219-41
[67]Veskova TK,Chimishkyan KL,Sver-Moldavsky GJ.Effect of Brucella abortus infection(vaccine strain 19BA)on Rauscher leukemia virus and L1210 leukemia in mice.J Natl Cancer Inst,1974,52:1651-3
[68]Schultz RM,Pavlidis NA,Chirigos MA.Macrophage involvement in the antitumor activity of Brucella abortus ether extract against experimental lung carcinoma metastases.Cancer Res,1978,38:3427-31
[69]Keleti G,Feingold DS,Youngner JS.Antitumor activity of a Brucella abortus preparation.Infect Immun,1977,15:846-9
[70]Chirigos MA,Stylos WA,Schultz RM et al.Chemical and biological adjuvants capable of potentiating tumor cell vaccine.Cancer Res,1978,38:1085-91
[71]Dazord L,Le Garrec Y,David C,et al.Resistance to transplanted cancer in mice increased by live Brucella vaccine.Br J Cancer,1978,38:464-7
[72]Dazord L,le Garrec Y,Florentin I.Antitumor activity of living or killed Brucella:modification of the non-specific cytotoxic effector cells.Cancer Immunol Immunother,1983,15:63-7
[73]Glasgow LA,Crane JJ,Schleupner CJ,et al.Enhancement of resistance to murine osteogenic sarcoma in vivo by an extract of Brucella abortus(Bru-Pel):association with activation of reticuloendothelial system macrophages.Infect Immun,1979,23:19-26
[74]Rossi AH,Farias A,Fernandez JE,et al.Brucella spp.lumazine synthase induces a TLR4-mediated protective response against B16 melanoma in mice.PLoS One,2015,10:e0126827
[75]Coria LM,Ibanez AE,Tkach M,et al.A Brucella spp.protease inhibitor limits antigen lysosomal proteolysis,increases cross-presentation,and enhances CD8+T cell responses.J Immunol,2016,196:4014-29
[76]Robert C.Checkpoint blockade plus oncolytic virus:a hot therapeutic cancer strategy.Trends Mol Med,2017,23:983-5